TP53-mut / del(17p) myeloma — high-risk cytogenetics composite; quadruplet (D-VRd; PERSEU...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-MUT-MM |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MM |
| Sources | SRC-CIVIC SRC-EHA-EMN-MM-2025 SRC-ESMO-MM-2023 SRC-NCCN-MM-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | any pathogenic mutation OR del(17p) |
| Disease | DIS-MM |
| ESCAT tier | IIA |
| Recommended combinations | D-VRd (1L transplant-eligible), Dara-Rd (1L transplant-ineligible), ide-cel / cilta-cel (R/R), alloSCT consideration in young high-risk |
| Evidence summary | TP53-mut / del(17p) myeloma — high-risk cytogenetics composite; quadruplet (D-VRd; PERSEUS) preferred over triplet. Maintenance with daratumumab/lenalidomide. CAR-T (ide-cel, cilta-cel) effective regardless of TP53 status. |
Notes
ESCAT IIA. Gene-level cell — biallelic vs monoallelic distinction matters in MDS/AML (biallelic = TP53-multihit per IPSS-M / ICC 2022, far worse). Per-hotspot cells provided for the most common variants.
Used By
No reverse references found in the YAML corpus.